232 related articles for article (PubMed ID: 24865288)
1. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
2. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
[TBL] [Abstract][Full Text] [Related]
3. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
4. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
6. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles.
Zhou Z; Li L; Yang Y; Xu X; Huang Y
Biomaterials; 2014 Aug; 35(24):6622-35. PubMed ID: 24814427
[TBL] [Abstract][Full Text] [Related]
7. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
8. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
9. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
Luo Y; Bernshaw NJ; Lu ZR; Kopecek J; Prestwich GD
Pharm Res; 2002 Apr; 19(4):396-402. PubMed ID: 12033370
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
[TBL] [Abstract][Full Text] [Related]
12. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
13. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral Distribution and pH-Dependent Drug Release of High Molecular Weight HPMA Copolymer Drug Conjugates Strongly Depend on Specific Tumor Substructure and Microenvironment.
Noack AK; Lucas H; Chytil P; Etrych T; Mäder K; Mueller T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825790
[TBL] [Abstract][Full Text] [Related]
15. Novel star HPMA-based polymer conjugates for passive targeting to solid tumors.
Etrych T; Strohalm J; Chytil P; Říhová B; Ulbrich K
J Drug Target; 2011 Dec; 19(10):874-89. PubMed ID: 21978286
[TBL] [Abstract][Full Text] [Related]
16. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T
Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594
[TBL] [Abstract][Full Text] [Related]
17. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
[TBL] [Abstract][Full Text] [Related]
18. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
19. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
20. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
